NL-OMON44680已完成2 期
Optimizing abiraterone (zytiga®)therapy by exploring the relation between an early biomarker-drug exposure-as a predictor for drug response in patients with mCRPC (OPTIMUM study) - OPTIMUM
Afdeling Apotheek0 个研究点目标入组 34 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* patients with metastatic castration resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated * OR * who have been treated upfront with 6 cycles of docetaxel: conform the Chaarted or Stampede trials
- •*Age *18 years
- •*Feasible to collect blood samples from
- •*Life expectancy of > 6 months
- •*Measurable disease
- •- Able and willing to give written informed consent prior to screening and enrollment
排除标准
- •Patients will be treated with abiraterone acetate in agreement with the drug label. Therefore the contra*indications of the drug label will be respected and no addi*tional strict exclusion criteria will be used in this study.
研究者
相似试验
进行中（未招募）
1 期
Is monitoring of plasmalevels of abiraterone a possible predictor for the response to Abiraterone treatment, in patients with metastatic prostate cancer?Metastatic Castration Resistant Prostate Cancer (mCRPC)MedDRA version: 19.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004513-90-NLRadboud UMC
已完成
不适用
Optimizing Abiraterone TherapyMetastatic Castration Resistant Prostate CancerNCT02426333Radboud University Medical Center56
已完成
3 期
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate CancerProstate CancerNCT01591122Janssen Research & Development, LLC313
已完成
2 期
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate CancerCastration-resistant Prostate CancerNCT02025010Dana-Farber Cancer Institute60
已完成
2 期
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate CancerProstate CancerNCT02218606Memorial Sloan Kettering Cancer Center81